Capstone Therapeutics Announces A Lipimetix Development, LLC Presentation At The American Heart Association Scientific Sessions: Pre-Clinical Data Demonstrating Significant Post Treatment Benefit Of AEM-28 On Established Atherosclerotic Lesions

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

TEMPE, Ariz. and BOSTON, Nov. 19, 2013 (GLOBE NEWSWIRE) -- Capstone Therapeutics' (OTCQB:CAPS) joint venture, LipimetiX Development, LLC, today announced the presentation of pre-clinical data demonstrating the sustained benefit effect of their apolipoprotein E mimetic peptide (AEM-28) on established atherosclerotic lesions in Apo E null mice at the American Heart Association Scientific Sessions meeting, November 16 – 20, 2013, in Dallas, TX.

Help employers find you! Check out all the jobs and post your resume.

Back to news